The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC).
Miriam Koopman
Consultant or Advisory Role - Amgen; Bayer; Merck Serono; Roche/Genentech; Sanofi
Lieke Simkens
No relevant relationships to disclose
Anne Maria May
No relevant relationships to disclose
Linda Mol
No relevant relationships to disclose
Harm van Tinteren
No relevant relationships to disclose
Cornelis J. A. Punt
Consultant or Advisory Role - Amgen; Bayer; Merck Serono; Roche/Genentech; Sanofi